Ultra-long-acting injectable, biodegradable, and removable in-situ forming implant with cabotegravir for HIV prevention
Journal of Controlled Release · 2025-10 · 386 · 114166
DOI: 10.1016/j.jconrel.2025.114166 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2025-10. Verfasst von Thy Le und 13 weiteren Autor:innen. Beteiligte Einrichtung: Lampe Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, N…. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Anti-HIV Agents. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, University of North Carolina, National Institutes of Health.
Abstract (Originalsprache)
HIV is a global health issue affecting approximately 40 million people worldwide, with low patient adherence being the primary challenge for maintaining effective pre-exposure prophylaxis (PrEP). Limitations of oral PrEP are mainly attributed to lack of adherence due to pill fatigue or stigma [1, 2]. Recently introduced long-acting injectables offer several advantages over daily PrEP, namely by improving adherence and improving efficacy [3-5]. The approved long-acting injectable Apretude® is administered every two months and elicits a long pharmacokinetic tail of >15 months that can lead to potential drug-resistant virus [6]. To address these limitations, we report on an ultra-long-acting injectable cabotegravir/barium sulfate (CAB/BaSO₄) in-situ forming implant (ISFI) capable of maintaining therapeutic CAB concentrations (> 4× PA-IC90) for up to 390 days. In this work, we optimized the ISFI formulation to include a contrast agent, BaSO4, to assess in vivo depot visualization and migration using X-ray imaging. CAB/BaSO4 ISFIs were investigated in vitro to determine CAB release kinetics, and in vivo to assess safety and pharmacokinetics in BALB/c mice. The CAB/BaSO₄ ISFI was well-tolerated and showed minimal to moderate signs of local inflammation and none to minimal systemic inflammation. At 24 hours post removal of the CAB/BaSO₄ ISFI, CAB plasma concentrations reached below the 1×PA-IC90 benchmark and below the limit of quantification within 14 days for 5 out of 6 mice. A full biodistribution study showed that CAB was mainly localized at the injection site subcutaneous tissue and plasma, with no detectable concentrations in other organs. Whole-body X-ray imaging showed that implants were visible for up to 268 days post administration with no noticeable migration. This is the first report of a CAB/BaSO₄ ISFI that is imageable, ultra-long-acting (>180 days), biodegradable, and removable, that can potentially revolutionize current HIV PrEP and help curb the global HIV epidemic.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lampe Joint Department of Biomedical Engineering, North Carolina State University and The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Division of Pharmacoengineering and Molecular Pharmaceutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Division of Comparative Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Förderung
- NIAID NIH HHS
- University of North Carolina
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases
- National Institute of Allergy and Infectious Diseases Division of Intramural Research
- University of North Carolina at Chapel Hill
- National Science Foundation
- Centre for Food and Allergy Research
Zitieren
APA
Le, T., Young, I. C., King, J. L., Cottrell, M. L., Kumbhar, A. S., Sykes, C., Schauer, A., De la Cruz, G., Kozuszek, C. T., Kalathil, N. C., Abel, A., Sellers, R. S., Kashuba, A. D. M., & Benhabbour, S. R. (2025). Ultra-long-acting injectable, biodegradable, and removable in-situ forming implant with cabotegravir for HIV prevention. Journal of Controlled Release, 386, 114166. https://doi.org/10.1016/j.jconrel.2025.114166
Vancouver
Le T, Young IC, King JL, Cottrell ML, Kumbhar AS, Sykes C, et al. Ultra-long-acting injectable, biodegradable, and removable in-situ forming implant with cabotegravir for HIV prevention. Journal of Controlled Release. 2025;386:114166. doi:10.1016/j.jconrel.2025.114166
BibTeX
@article{Le2025,
author = {Le, Thy and Young, Isabella C and King, Jasmine L and Cottrell, Mackenzie L and Kumbhar, Amar Shankar and Sykes, Craig and Schauer, Amanda and De la Cruz, Gabriela and Kozuszek, Caleb T and Kalathil, Nanditha Chundayil and Abel, Alexandra and Sellers, Rani S and Kashuba, Angela D M and Benhabbour, S Rahima},
title = {Ultra-long-acting injectable, biodegradable, and removable in-situ forming implant with cabotegravir for HIV prevention},
journal = {Journal of Controlled Release},
year = {2025},
volume = {386},
pages = {114166},
doi = {10.1016/j.jconrel.2025.114166}
}
EUVIMED